Fusion Antibodies reports strong revenue growth in third quarter

Clarendon Portfolio company Fusion Antibodies a clinical research firm has reported a strong revenue performance during the third quarter.

In a trading update on Wednesday, the publicly listed company said it expects revenues for the year ending March 31 2020 to be significantly ahead of current market expectations, and above the previous year (£2.2 million).

The company said the revenue growth is largely a result of an increase in sales of existing services. But it said the contribution from newer high margin services has yet to be fully achieved to the extent previously anticipated.

Accordingly, the Fusion said it expects gross profit margin for the current financial year to be marginally below current market expectations but ahead of that achieved last year.

Share the Post:

Related Posts

CFM and Ilimex

ILIMEX Announces Conclusion of Funding Round Raising £600,000 (c.€700,000) In Equity Finance

ILIMEX, the Northern Ireland-based provider of biosecurity and air sterilisation solutions, is pleased to announce the conclusion of a funding round which has raised additional equity finance of £600,000 (c. €700,000). This funding will be used to validate the performance of ILIMEX’s Flufence air sterilisation solutions and fund its entry into the agri-food sector with an initial focus on poultry and medicinal mushroom production.

Read More

Join Clarendon Fund Managers as Portfolio and Finance Manager

Clarendon Fund Managers, a B Corp-certified venture capital firm based in Belfast, is looking for a Portfolio and Finance Manager to join our growing team. With a mission to back high-potential companies and drive economic growth in Northern Ireland, we support a diverse and inclusive culture where collaboration, impact and excellence are at the core of what we do.

Read More